It's not quite that complex, but your ( and all your 'friends" ) attention to my commentary is a "tell"

It's likely a coincidence that you make what appear to be positive ( oh, and HIGH END ) observations about illiquid bio-techs that share the same consultants and IR firms.

* Like negative posting on YM Bio in the dollar range, before they were taken out at $3
* Or the concept that Spectral likely had 10 years to go for full "drug approval"
* I like your attention to the T.CUR board...an insider buys and you remind us all that the CEO has BOUGHT NOTHING ( I like the Good news / Bad News angle )
* I think you understand the danger of CEO's buying illiquid bio-techs...tends to make them GO UP
* Then there's the Lexus lease coverage
* How bout that BNC financing...still "Not going well" ?

You should post a list of questions "you'll answer" - my favourite Dube moment

No Rube, I'm afraid you're trouble, but It would seem that buying stocks that you "analyze" is a good move.

I should post your detailed thank yous to me, as I "set you on the correct path" during the "openning of Spectral's backdoor" over at Meddwell....you're familiar with Meddwell..right Dube ?

Bless your tainted $oul,
Sqr